CancerVax Corporation Announces Fourth Quarter and Full Year 2004 Financial Results.
Business Wire › February 17, 2005
Linked as:
Extract
CancerVax Corporation Announces Fourth Quarter and Full Year 2004 Financial Results.
CARLSBAD, Calif. -- CancerVax Corporation (NASDAQ:CNVX), a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer, announced today its unaudited financial results for the fourth quarter and year ended December 31, 2004. For the fourth quarter ended December 31, 2004, CancerVax reported a net loss of $14.3 million, as compared to a net loss of $11.1 million for the same period in 2003. For the year ended December 31, 2004, CancerVax reported a net loss of $55.6 million, as compared to a net loss of $37.6 million for the same period in 2003.
In December 2004, CancerVax announced the signing of a worldwide collaboration agreement with Serono for the development and commercialization of Canvaxin(TM), an investigational specific active immunotherapy product candidate being developed for the treatment of advanced-stage melanoma. CancerVax and Serono will co-promote Canvaxin in the U.S. and share equally certain expenses and profits. Outside the U.S., Serono will have the exclusive right to commercialize Canvaxin and will p...See the full content of this document
Sponsored links
